严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）德尔塔变异株：对疫苗有效性的持续威胁。 - Suppr

Suppr

超能文献

SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines.

作者信息

Thiruvengadam Ramachandran, Binayke Akshay, Awasthi Amit

机构信息

Translational Health Science and Technology Institute, Faridabad, India.

出版信息

Lancet Infect Dis. 2022 Mar;22(3):301-302. doi: 10.1016/S1473-3099(21)00697-6. Epub 2021 Nov 23.

DOI:10.1016/S1473-3099(21)00697-6

PMID:34826382

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8610239/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd2e/8610239/d296d039f209/fx1_lrg.jpg

相似文献

SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）德尔塔变异株：对疫苗有效性的持续威胁。

Lancet Infect Dis. 2022 Mar;22(3):301-302. doi: 10.1016/S1473-3099(21)00697-6. Epub 2021 Nov 23.

Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.在广州，灭活的 SARS-CoV-2 疫苗对 Delta 变异株感染的有效性：一项病例对照的真实世界研究。

Emerg Microbes Infect. 2021 Dec;10(1):1751-1759. doi: 10.1080/22221751.2021.1969291.

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。

MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗与病毒变体日益增长的威胁

JAMA. 2021 Mar 2;325(9):821-822. doi: 10.1001/jama.2021.1114.

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021.新冠病毒疫苗在 B.1.617.2（德尔塔）变异株流行前后预防一线工作人员感染 SARS-CoV-2 的效果-2020 年 12 月至 2021 年 8 月美国 8 个地点。

MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1167-1169. doi: 10.15585/mmwr.mm7034e4.

Confronting the Delta Variant of SARS-CoV-2, Summer 2021.应对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的德尔塔变异株，2021年夏季

JAMA. 2021 Sep 21;326(11):1001-1002. doi: 10.1001/jama.2021.14811.

Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021.2021 年以色列 SARS-CoV-2 德尔塔变异株感染爆发期间 BNT162b2 疫苗在青少年中的有效性。

Emerg Infect Dis. 2021 Nov;27(11):2919-2922. doi: 10.3201/eid2711.211886. Epub 2021 Sep 27.

COVID vaccine makers brace for a variant worse than Delta.新冠疫苗制造商为应对比德尔塔毒株更糟糕的变异毒株做准备。

Nature. 2021 Oct;598(7882):552-553. doi: 10.1038/d41586-021-02854-3.

Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021.2021 年 8 月至 9 月，在德尔塔变异株（B.1.617.2）占主导地位期间，疫苗对向家庭接触者传播 SARS-CoV-2 的有效性，荷兰。

Euro Surveill. 2021 Nov;26(44). doi: 10.2807/1560-7917.ES.2021.26.44.2100977.

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.BNT162b2疫苗诱导产生的针对真实B.1、B.1.1.7、B.1.351、B.1.525和P.1型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的中和抗体血清学调查

Emerg Microbes Infect. 2021 Dec;10(1):1241-1243. doi: 10.1080/22221751.2021.1940305.

引用本文的文献

Clinical and experimental evidence suggest omicron variant of SARS-CoV-2 is inherently less pathogenic than delta variant independent of previous immunity.临床和实验证据表明，奥密克戎变异株 SARS-CoV-2 的致病性低于德尔塔变异株，而与既往免疫无关。

Eur J Med Res. 2023 Oct 11;28(1):421. doi: 10.1186/s40001-023-01373-3.

Longitudinal clinical phenotyping of post COVID condition in Mexican adults recovering from severe COVID-19: a prospective cohort study.墨西哥成年重症COVID-19康复者新冠后状况的纵向临床表型分析：一项前瞻性队列研究

Front Med (Lausanne). 2023 Aug 24;10:1236702. doi: 10.3389/fmed.2023.1236702. eCollection 2023.

Modeling the XBB strain of SARS-CoV-2: Competition between variants and impact of reinfection.建模 SARS-CoV-2 的 XBB 株：变种之间的竞争和再感染的影响。

J Theor Biol. 2023 Oct 7;574:111611. doi: 10.1016/j.jtbi.2023.111611. Epub 2023 Aug 26.

Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants.灭活疫苗诱导产生的强效抗体可以广泛中和流行的 SARS-CoV-2 变异株。

Nat Commun. 2023 Apr 17;14(1):2179. doi: 10.1038/s41467-023-37926-7.

Post COVID-19 pulmonary complications in outpatient setting: Insights from a cross-sectional study in a rural academic hospital.门诊环境中的新冠后肺部并发症：农村学术医院横断面研究的见解。

Am J Emerg Med. 2023 Jun;68:124-126. doi: 10.1016/j.ajem.2023.03.031. Epub 2023 Mar 23.

Molecular determinants associated with temporal succession of SARS-CoV-2 variants in Uttar Pradesh, India.印度北方邦与新冠病毒变异株时间序列相关的分子决定因素

Front Microbiol. 2023 Feb 1;14:986729. doi: 10.3389/fmicb.2023.986729. eCollection 2023.

Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19.促炎先天性细胞因子和独特的代谢组学特征塑造了活跃型新冠肺炎中的T细胞反应。

Vaccines (Basel). 2022 Oct 20;10(10):1762. doi: 10.3390/vaccines10101762.

Diagnostic Tools for Rapid Screening and Detection of SARS-CoV-2 Infection.用于快速筛查和检测新型冠状病毒2019感染的诊断工具

Vaccines (Basel). 2022 Jul 28;10(8):1200. doi: 10.3390/vaccines10081200.

Autophagy and evasion of the immune system by SARS-CoV-2. Structural features of the non-structural protein 6 from wild type and Omicron viral strains interacting with a model lipid bilayer.自噬与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对免疫系统的逃避。野生型和奥密克戎病毒株非结构蛋白6与模型脂质双层相互作用的结构特征。

Chem Sci. 2022 May 2;13(20):6098-6105. doi: 10.1039/d2sc00108j. eCollection 2022 May 25.

Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines.在源头阻击入侵者：黏膜抗SARS-CoV-2疫苗的前景

Pathogens. 2022 Jan 19;11(2):117. doi: 10.3390/pathogens11020117.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验